Aditxt, Inc. Other Operating Income (Expense), Net
Aditxt, Inc. (ADTX) reported Other Operating Income (Expense), Net of $8.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2025-03-31
- Aditxt, Inc. other operating income (expense), net for fiscal 2024 was $8.10M, a 30.65% increase from fiscal 2023.
- Aditxt, Inc. other operating income (expense), net for fiscal 2023 was $6.20M.
| Period end | Other Operating Income (Expense), Net 12 month |
|---|---|
| 2024-12-31 | $8.10M 10-K · filed 2025-03-31 |
| 2023-12-31 | $6.20M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |